Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses hirsutism management guidelines, recommending androgen testing only for women with abnormal hirsutism scores and advocating for combined therapy approaches depending on severity and underlying conditions, but it reports no new clinical results.

This review discusses the epidemiology, causes, diagnosis, and management of hirsutism in women, noting that effective treatment requires addressing the root cause as well as the hair growth.

This review examines various methods for assessing hair growth in women, highlighting the usefulness of the mFG visual scoring method for diagnosing hirsutism despite its limitations.

This article discusses evaluation and treatment options for a 19-year-old woman with slowly progressive hair growth and reports no new clinical findings.

This review discusses the diagnosis and treatment of hirsutism, emphasizing that a systematic evaluation can determine its cause, while combination therapy effectively manages the condition for most patients.

This study suggests that metformin may be more effective than Dianette in treating moderate to severe hirsutism in women with PCOS, while also reducing markers of insulin resistance.

This study found that shorter CAG-repeat lengths in the androgen receptor may be associated with the development of androgen-mediated skin disorders like androgenetic alopecia, acne, and hirsutism in both men and women.

This study reported that spironolactone at 200 mg/day significantly improved facial hair growth in women with hirsutism and showed a sustained reduction in ovarian androgens over one year.

This article discusses treatments for hirsutism and acne in women with polycystic ovary syndrome, suggesting that lower doses of current medications maintain efficacy while reducing cost and side effects, but reports no new clinical results.

This study found that flutamide was more effective than spironolactone in reducing symptoms of hirsutism and related conditions in premenopausal women, with fewer discontinuations due to side effects.

This study suggests that antiandrogens may slightly reduce hirsutism severity compared to placebo, but evidence is weak and their relative efficacy remains uncertain.

This study found that spironolactone reduced serum androstenedione and anagen hair shaft diameter in hirsute patients but did not significantly alter unbound testosterone levels, suggesting its effects are primarily peripheral.

In this study of women with hirsutism or androgenic alopecia, diverse underlying endocrine disorders including polycystic ovaries and various enzyme deficiencies were detected, often associated with elevated testosterone levels.

This study found that combining flutamide with an oral contraceptive significantly reduced hirsutism, acne, and seborrhea in patients after seven months, without significant side effects.

This study found that spironolactone significantly reduced hair growth in hirsute women, with noticeable effects in 3-5 months, and decreased serum testosterone levels in all participants.

Insulin sensitizers may slightly reduce hirsutism but are less effective than other treatments.

This study found that all four treatments—flutamide, finasteride, ketoconazole, and EE-CPA—significantly reduced hirsutism, but EE-CPA and flutamide appeared most effective, with varying effects on androgen levels and side-effect profiles.

This study found that ethinylestradiol and high-dose cyproterone acetate significantly reduced hirsutism scores and were effective for treating acne and alopecia in women with hyperandrogenism.

This article discusses oral spironolactone therapy for female patients with acne, hirsutism, or androgenic alopecia and reports no new clinical results.

This study found that ovarian suppression significantly reduced serum testosterone and androstenedione in women with polycystic ovarian syndrome and idiopathic hirsutism, with hair growth rates decreasing more in polycystic ovarian syndrome.

This study determined that an mFG score of 5 or greater defines hirsutism among Southern Chinese women, with prevalence and score thresholds decreasing with age.

This study found that spironolactone, flutamide, and finasteride are similarly effective in reducing hair diameter and Ferriman-Gallwey scores in women with hirsutism over a 6-month treatment period.

In this study, cyproterone acetate at 2 mg daily was found to be as effective as higher doses in reducing hair growth for hirsute women over 12 months.

This study found that metformin treatment significantly improved hair growth in women with PCOS and hirsutism compared to a placebo.

This study found that shaving was the most helpful and commonly used temporary hair removal method among women with facial hirsutism.

This study observed that high-dose spironolactone frequently caused metrorrhagia in women with idiopathic hirsutism, leading the authors to suggest lower starting doses or additional hormonal therapy.

This study found that in hirsute women, daily treatment with 200 mg spironolactone significantly reduced hair growth rates and hair shaft diameters on various body areas over 12 months.

This study found that both finasteride and flutamide effectively reduce hirsutism in women with polycystic ovary syndrome or idiopathic hirsutism, but flutamide was more effective.

This study concluded that finasteride, cyproterone acetate, and flutamide were similarly effective at reducing hirsutism in women, though they acted through different mechanisms.

This study found that finasteride effectively reduced hirsutism in women during 12 months of treatment, with some effects persisting in the majority after stopping the medication.